Osteoporos Sarcopenia.  2017 Jun;3(2):75-81. 10.1016/j.afos.2017.05.002.

Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms

Affiliations
  • 1Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. divyavohora@hotmail.com
  • 2Pharmaceutical Medicine, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
  • 3Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are currently the treatment of choice in depression and constitute major portion of prescription in depressive patients. The role of serotonin receptors in bone is emerging, raising certain questions regarding the effect of blockade of serotonin reuptake in the bone metabolism. Clinical studies have reported an association of SSRI antidepressants which with increase in fracture and decrease in bone mineral density. This review focus on recent evidence that evaluate the association of SSRIs with the risk of fracture and bone mineral density and also the probable mechanisms that might be involved in such effects.

Keyword

Selective serotonin reuptake inhibitors; Fracture; Bone mineral density; Serotonin; Bone

MeSH Terms

Antidepressive Agents
Bone Density
Depression
Humans
Metabolism
Prescriptions
Receptors, Serotonin
Serotonin Uptake Inhibitors*
Serotonin*
Antidepressive Agents
Receptors, Serotonin
Serotonin
Serotonin Uptake Inhibitors
Full Text Links
  • OS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr